Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy.

DeVeaux M, Kane M, Wei W, Zelterman D.

Pharm Stat. 2019 Sep 10. doi: 10.1002/pst.1965. [Epub ahead of print]

PMID:
31507079
2.

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.

Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL.

J Immunother Cancer. 2019 Jul 23;7(1):194. doi: 10.1186/s40425-019-0675-0.

3.

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.

Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K.

J Immunother Cancer. 2019 Jul 10;7(1):172. doi: 10.1186/s40425-019-0643-8.

4.

A parametric meta-analysis.

Yu C, Zelterman D.

Stat Med. 2019 Sep 20;38(21):4013-4025. doi: 10.1002/sim.8278. Epub 2019 Jun 17.

PMID:
31206759
5.

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.

Truini A, Starrett JH, Stewart TF, Ashtekar KD, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K.

Clin Cancer Res. 2019 Jun 10. pii: clincanres.0780.2019. doi: 10.1158/1078-0432.CCR-19-0780. [Epub ahead of print]

PMID:
31182434
6.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.

Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141. [Epub ahead of print]

7.

Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation.

Rahimy E, Weidhaas J, Wei W, Lannin D, Horowitz N, Higgins S, Wilson LD, Knowlton C, Moran MS, Young MR, Killelea B, Chagpar A, Yeboa DN, Zelterman D, Evans S.

Pract Radiat Oncol. 2019 May;9(3):e257-e265. doi: 10.1016/j.prro.2019.01.013. Epub 2019 Feb 20.

PMID:
30796975
8.

Clinical Trial Design Using A Stopped Negative Binomial Distribution.

DeVeaux M, Kane MJ, Zelterman D.

Stat Interface. 2018;11(4):699-707. doi: 10.4310/SII.2018.v11.n4.a13. Epub 2018 Sep 19.

9.

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.

Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL.

Clin Cancer Res. 2019 Apr 15;25(8):2442-2449. doi: 10.1158/1078-0432.CCR-18-2652. Epub 2019 Jan 7.

PMID:
30617133
10.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA.

Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8.

11.

Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.

Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S.

Ann Hematol. 2019 Jan;98(1):237-240. doi: 10.1007/s00277-018-3427-1. Epub 2018 Jul 19. No abstract available.

PMID:
30027436
12.

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.

Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS.

J Thorac Oncol. 2018 Jun;13(6):831-839. doi: 10.1016/j.jtho.2018.03.008. Epub 2018 Mar 22.

13.

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger SN, Wilson LD, Herbst RS, Patel AA.

Clin Cancer Res. 2018 Apr 15;24(8):1872-1880. doi: 10.1158/1078-0432.CCR-17-1341. Epub 2018 Jan 12.

14.

DNA polymerase beta participates in DNA End-joining.

Ray S, Breuer G, DeVeaux M, Zelterman D, Bindra R, Sweasy JB.

Nucleic Acids Res. 2018 Jan 9;46(1):242-255. doi: 10.1093/nar/gkx1147.

15.

A parametric model to estimate the proportion from true null using a distribution for p-values.

Yu C, Zelterman D.

Comput Stat Data Anal. 2017 Oct;114:105-118. doi: 10.1016/j.csda.2017.04.008. Epub 2017 Apr 29.

16.

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.

Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV.

Clin Lymphoma Myeloma Leuk. 2017 May;17(5):296-304.e2. doi: 10.1016/j.clml.2017.02.025. Epub 2017 Mar 7.

17.

DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy.

Nemec AA, Abriola L, Merkel JS, de Stanchina E, DeVeaux M, Zelterman D, Glazer PM, Sweasy JB.

Mol Cancer Res. 2017 Mar;15(3):269-280. doi: 10.1158/1541-7786.MCR-16-0227-T. Epub 2017 Jan 10.

18.

A general approximation to quantiles.

Yu C, Zelterman D.

Commun Stat Theory Methods. 2017;46(19):9834-9841. doi: 10.1080/03610926.2016.1222433. Epub 2017 Jul 10.

19.

Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.

Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM.

Transfusion. 2017 Feb;57(2):289-295. doi: 10.1111/trf.13934. Epub 2016 Nov 22.

20.

Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.

Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C.

Biometrics. 2017 Jun;73(2):687-695. doi: 10.1111/biom.12590. Epub 2016 Sep 26.

21.

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.

McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB.

Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11.

22.

Markov counting models for correlated binary responses.

Crawford FW, Zelterman D.

Biostatistics. 2015 Jul;16(3):427-40. doi: 10.1093/biostatistics/kxv006. Epub 2015 Mar 19.

23.

Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.

Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, DiGiovanna MP, Harris L, Abu-Khalaf MM.

Breast Cancer Res Treat. 2015 Feb;150(1):157-67. doi: 10.1007/s10549-015-3292-8. Epub 2015 Feb 17.

PMID:
25687356
24.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.

Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN.

Cancer. 2015 Jun 1;121(11):1817-26. doi: 10.1002/cncr.29254. Epub 2015 Feb 3.

25.

A spatial simulation approach to account for protein structure when identifying non-random somatic mutations.

Ryslik GA, Cheng Y, Cheung KH, Bjornson RD, Zelterman D, Modis Y, Zhao H.

BMC Bioinformatics. 2014 Jul 3;15:231. doi: 10.1186/1471-2105-15-231.

26.

Methylation of twelve CpGs in human papillomavirus type 16 (HPV16) as an informative biomarker for the triage of women positive for HPV16 infection.

Brandsma JL, Harigopal M, Kiviat NB, Sun Y, Deng Y, Zelterman D, Lizardi PM, Shabanova VS, Levi A, Yaping T, Hu X, Feng Q.

Cancer Prev Res (Phila). 2014 May;7(5):526-33. doi: 10.1158/1940-6207.CAPR-13-0354. Epub 2014 Feb 20.

27.

Mutation of POLB causes lupus in mice.

Senejani AG, Liu Y, Kidane D, Maher SE, Zeiss CJ, Park HJ, Kashgarian M, McNiff JM, Zelterman D, Bothwell AL, Sweasy JB.

Cell Rep. 2014 Jan 16;6(1):1-8. doi: 10.1016/j.celrep.2013.12.017. Epub 2014 Jan 2.

28.

Natural ventilation reduces high TB transmission risk in traditional homes in rural KwaZulu-Natal, South Africa.

Lygizos M, Shenoi SV, Brooks RP, Bhushan A, Brust JC, Zelterman D, Deng Y, Northrup V, Moll AP, Friedland GH.

BMC Infect Dis. 2013 Jul 1;13:300. doi: 10.1186/1471-2334-13-300.

29.

Beta prime regression with application to risky behavior frequency screening.

Tulupyev A, Suvorova A, Sousa J, Zelterman D.

Stat Med. 2013 Oct 15;32(23):4044-56. doi: 10.1002/sim.5820. Epub 2013 Apr 25.

30.

The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.

Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP.

PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25.

31.

Human POLB gene is mutated in high percentage of colorectal tumors.

Donigan KA, Sun KW, Nemec AA, Murphy DL, Cong X, Northrup V, Zelterman D, Sweasy JB.

J Biol Chem. 2012 Jul 6;287(28):23830-9. doi: 10.1074/jbc.M111.324947. Epub 2012 May 10.

32.

Geographic poverty and racial/ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009.

Niccolai LM, Julian PJ, Bilinski A, Mehta NR, Meek JI, Zelterman D, Hadler JL, Sosa L.

Am J Public Health. 2013 Jan;103(1):156-63. doi: 10.2105/AJPH.2011.300447. Epub 2012 Apr 19.

33.

Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa.

Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH.

PLoS One. 2012;7(3):e31786. doi: 10.1371/journal.pone.0031786. Epub 2012 Mar 6.

34.

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

35.

Comparative risks of non-prescription analgesics: a structured topic review and research priorities.

Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC.

Expert Opin Drug Saf. 2012 Jan;11(1):33-44. doi: 10.1517/14740338.2012.629782. Epub 2011 Oct 20. Review.

PMID:
22010836
36.

Fructosamine reference ranges in rhesus macaques (Macaca mulatta).

Williams-Fritze MJ, Smith PC, Zelterman D, Scholz JA.

J Am Assoc Lab Anim Sci. 2011 Jul;50(4):462-5.

37.

A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.

Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J.

Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22. Erratum in: Lancet Oncol. 2011 Jun;12(6):522.

38.

DNA polymerase beta is critical for genomic stability of sperm cells.

Kidane D, Dalal S, Keh A, Liu Y, Zelterman D, Sweasy JB.

DNA Repair (Amst). 2011 Apr 3;10(4):390-7. doi: 10.1016/j.dnarep.2011.01.003. Epub 2011 Feb 18.

39.

Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.

Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB.

Cell Cycle. 2011 Jan 1;10(1):90-9. Epub 2011 Jan 1.

40.

Should the 7th edition of the lung cancer stage classification system change treatment algorithms in non-small cell lung cancer?

Boffa DJ, Detterbeck FC, Smith EJ, Rami-Porta R, Crowley J, Zelterman D, Tanoue L, Kim AW, Goldstraw P.

J Thorac Oncol. 2010 Nov;5(11):1779-83. doi: 10.1097/JTO.0b013e3181ee80c7.

41.

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB.

Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20.

42.

WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A.

Booth CJ, Brooks MB, Rockwell S, Murphy JW, Rinder HM, Zelterman D, Paidas MJ, Compton SR, Marks PW.

J Thromb Haemost. 2010 Nov;8(11):2472-7. doi: 10.1111/j.1538-7836.2010.03978.x.

43.

Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis.

Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell AL.

Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5540-4. doi: 10.1073/pnas.0912675107. Epub 2010 Mar 8.

44.

Metachronous primary melanoma and lymphoma.

McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D.

Ann Plast Surg. 2010 Feb;64(2):229-32. doi: 10.1097/SAP.0b013e3181a13dbf.

PMID:
20098111
45.

DNA polymerase beta is critical for mouse meiotic synapsis.

Kidane D, Jonason AS, Gorton TS, Mihaylov I, Pan J, Keeney S, de Rooij DG, Ashley T, Keh A, Liu Y, Banerjee U, Zelterman D, Sweasy JB.

EMBO J. 2010 Jan 20;29(2):410-23. doi: 10.1038/emboj.2009.357. Epub 2009 Dec 17.

46.

Statistical design for a small serial dilution series.

Zelterman D, Tulupyev A, Heimer R, Abdala N.

Stat Med. 2010 Feb 10;29(3):411-20. doi: 10.1002/sim.3774.

47.

Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity.

Kim Y, Lin Q, Zelterman D, Yun Z.

Cancer Res. 2009 Dec 15;69(24):9271-80. doi: 10.1158/0008-5472.CAN-09-1605.

48.

Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Brandsma JL, Shlyankevich M, Su Y, Zelterman D, Rose JK, Buonocore L.

Vaccine. 2010 Dec 6;28(52):8345-51. doi: 10.1016/j.vaccine.2009.04.082. Epub 2009 Jul 15.

49.

Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy.

Brandsma JL, Sun Y, Lizardi PM, Tuck DP, Zelterman D, Haines GK 3rd, Martel M, Harigopal M, Schofield K, Neapolitano M.

Virology. 2009 Jun 20;389(1-2):100-7. doi: 10.1016/j.virol.2009.03.029. Epub 2009 May 13.

50.

Pruritic and nociceptive sensations and dysesthesias from a spicule of cowhage.

LaMotte RH, Shimada SG, Green BG, Zelterman D.

J Neurophysiol. 2009 Mar;101(3):1430-43. doi: 10.1152/jn.91268.2008. Epub 2009 Jan 14.

Supplemental Content

Loading ...
Support Center